161 related articles for article (PubMed ID: 25849628)
1. A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo.
Rozanov D; Spellman P; Savinov A; Strongin AY
PLoS One; 2015; 10(4):e0122980. PubMed ID: 25849628
[TBL] [Abstract][Full Text] [Related]
2. Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells.
Rozanov DV; Savinov AY; Golubkov VS; Rozanova OL; Postnova TI; Sergienko EA; Vasile S; Aleshin AE; Rega MF; Pellecchia M; Strongin AY
Mol Cancer Ther; 2009 Jun; 8(6):1515-25. PubMed ID: 19509255
[TBL] [Abstract][Full Text] [Related]
3. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.
Yan J; Wang L; Wang Z; Wang Z; Wang B; Zhu R; Bi J; Wu J; Zhang H; Wu H; Yu B; Kong W; Yu X
Cell Death Dis; 2016 Jun; 7(6):e2274. PubMed ID: 27336718
[TBL] [Abstract][Full Text] [Related]
4. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y
Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054
[TBL] [Abstract][Full Text] [Related]
5. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
6. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.
Aronin A; Amsili S; Prigozhina TB; Tzdaka K; Rachmilewitz J; Shani N; Tykocinski ML; Dranitzki Elhalel M
PLoS One; 2013; 8(10):e77050. PubMed ID: 24130833
[TBL] [Abstract][Full Text] [Related]
7. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
8. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
10. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Qiu F; Hu M; Tang B; Liu X; Zhuang H; Yang J; Hua ZC
Sci Rep; 2013 Dec; 3():3565. PubMed ID: 24356445
[TBL] [Abstract][Full Text] [Related]
11. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
13. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
14. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Ashkenazi A; Holland P; Eckhardt SG
J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
[TBL] [Abstract][Full Text] [Related]
15. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.
Rozga P; Kloska D; Pawlak S; Teska-Kaminska M; Galazka M; Bukato K; Pieczykolan A; Jaworski A; Molga-Kaczmarska A; Kopacz A; Badyra B; Kachamakova-Trojanowska N; Zolnierkiewicz O; Targosz-Korecka M; Poleszak K; Szymanik M; Zerek B; Pieczykolan J; Jozkowicz A; Grochot-Przeczek A
Int J Cancer; 2020 Aug; 147(4):1117-1130. PubMed ID: 31863596
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
17. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
